Definitions of measures of effect duration for psoriasis treatments

被引：46

作者：

Gordon, KB ^{[1
]}

Feldman, SR ^{[1
]}

Koo, JYM ^{[1
]}

Menter, A ^{[1
]}

Rolstad, T ^{[1
]}

Krueger, G ^{[1
]}

机构：

[1] Loyola Univ, Stritch Sch Med, Div Dermatol, Dept Med, Maywood, IL 60153 USA

来源：

ARCHIVES OF DERMATOLOGY | 2005年 / 141卷 / 01期

关键词：

D O I：

10.1001/archderm.141.1.82

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：82 / 84

页数：3

共 4 条

[1] Clearance is not a realistic expectation of psoriasis treatment [J].

Al-Suwaidan, SN ;

Feldman, SR .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (05) :796-802

[2] A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis [J].

Carlin, CS ;

Feldman, SR ;

Krueger, JG ;

Menter, A ;

Krueger, GG .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (06) :859-866

[3] Duration of remission of psoriasis therapies [J].

Koo, J ;

Lebwohl, M .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (01) :51-59

[4] Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? [J].

Krueger, GG ;

Feldman, SR ;

Camisa, C ;

Duvic, M ;

Elder, JT ;

Gottlieb, AB ;

Koo, J ;

Krueger, JG ;

Lebwohl, M ;

Lowe, N ;

Menter, A ;

Morison, WL ;

Prystowsky, JH ;

Shupack, JL ;

Taylor, JR ;

Weinstein, GD ;

Barton, TL ;

Rolstad, T ;

Day, RM .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (02) :281-285

← 1 →